Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Alveolar Macrophages in Individuals With COPD Versus Smokers With Normal Pulmonary Function

NCT00281190

Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive

COMPLETED

Regulation of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease

NCT00147095

COPD Emphysema

COMPLETED

Lung Microbiome and Inflammation in Early COPD

NCT02777879

Chronic Obstuctive Pulmonary Disease

RECRUITING

Mechanisms and Impact of Bacterial Colonisation in COPD

NCT03161561

COPD

COMPLETED NA

Comparison of Alveolar Macrophages in Healthy Individuals Versus Individuals With COPD

NCT00281203

Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot observational study of 20 subjects ≥40 years of age with smoking history of at least 20 pack-years (former or current) who have preserved spirometry, as defined by normal Forced Expiratory Volume (FEV1) / Forced Vital Capacity (FVC). Of the 20 subjects, 10 with and 10 without air trapping as determined by high and abnormal versus low and normal Residual Volume (RV) / Total Lung Capacity (TLC) measured by plethysmography. The cohort will undergo extensive clinical characterization including full Pulmonary Function Testing (PFT) and medical, symptom, activity, and quality of life questionnaires assessment including modified Medical Council Research (mMRC), COPD Assessment Test (CAT), Short Form-12 (SF12), and St. George's Respiratory (SGRQ) questionnaires. Subjects will undergo bronchoscopy with bronchoalveolar lavage (BAL) to obtain luminal macrophages and BAL fluid (BALF). Live BAL cells, BALF, and BAL cell RNA will be collected and stored in our biorepository for proposed studies. Molecular, functional, and transcriptomics analyses of luminal (alveolar) macrophages obtained by BAL (Aim 2) and protease activity measurement in serum and BALF will be performed (Aim 2) and will be examined against the clinical phenotype of the subjects, in particular air trapping-phenotype, to see if an underlying biological signature for susceptibility to develop COPD could be identified.

To perform a more comprehensive molecular and functional phenotype examination of lung macrophages, additional methodologies will be developed including a second mass cytometry (CyTOF) panel for single-cell proteomics and CyTOF-based phagocytosis and efferocytosis assays to allow for performance of truly single-cell functional phenotyping of myeloid cells from BAL and lung tissue (Aim 1).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Copd Smoking Tobacco Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal RV/TLC Group:

Plethysmographic RV/TLC equal or less than lower limit of normal.

Bronchoscopy with Bronchoalveolar Lavage (BAL)

Intervention Type PROCEDURE

1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).
2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.
3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.
4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.
5. Blood draw
6. Medical Health and Symptom Questionnaires
7. Physical Exam by study doctor to determine suitability and safety for participation.

Abnormal RV/TLC Group:

Plethysmographic RV/TLC higher than lower limit of normal.

Bronchoscopy with Bronchoalveolar Lavage (BAL)

Intervention Type PROCEDURE

1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).
2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.
3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.
4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.
5. Blood draw
6. Medical Health and Symptom Questionnaires
7. Physical Exam by study doctor to determine suitability and safety for participation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bronchoscopy with Bronchoalveolar Lavage (BAL)

1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).
2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.
3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.
4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.
5. Blood draw
6. Medical Health and Symptom Questionnaires
7. Physical Exam by study doctor to determine suitability and safety for participation.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Albuterol Administration Peak Flow Measurement Pulmonary Function Test (with Spirometry) Blood draw Medical Health and Symptom Questionnaires Physical Exam

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages between 40 to 75 years old.
* History of at least 20 pack-years of smoking.
* No diagnosis of COPD or asthma.
* No spirometric evidence of airflow obstruction as determined by FEV1/FVC ratio ≥0.7.
* FEV1 and FVC \>lower limit of normal.
* Less than 1 pack-year history of tobacco smoking and no tobacco use within the past 12 months.
* Subjects will be divided into two groups by their RV/TLC:

Normal RV/TLC Group:

• Plethysmographic RV/TLC equal or less than lower limit of normal.

Abnormal RV/TLC Group:

• Plethysmographic RV/TLC higher than lower limit of normal.

Exclusion Criteria

* Any history of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 times IV drug usage. C- longer than 1 year usage.
* Marijuana use \>400 joints in lifetime or any within past 6 months.
* Inability to walk briskly, run on treadmill, or pedal on ergometer to perform the study-required exercise level.
* Pregnant/breast feeding.
* Serious and active heart conditions- defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy.
* Liver cirrhosis.
* History of chronic active Hepatitis B or C.

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes